denosumab
daiichi sankyo,amgen
['denosumab']
l05 #acr22 high-dose denosumab in erosive hand oa
48wk, double-blind pbo phase 2 100 patients
guss change higher in den v pbo at w24, incr at w48
new erosions lower in den w48 (2% v 7%, or 0.23, p&lt;0.001)
open label extension w improvement to baseline 
Rheumatologist at Institute for Rheumatic and Autoimmune Disease at Overlook Hospital, proud Hopkins alum, health care advocate, Eagles fan entering Giants land